Orforglipron

Orforglipron (brand name Foundayo) is an oral small molecule that activates the glucagon-like peptide-1 (GLP-1) receptor. It was developed as a once-daily tablet for chronic weight management and type 2 diabetes, and it does not need the strict empty-stomach dosing required by oral semaglutide The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron+1. Because it is not a peptide, it achieves high oral absorption without an absorption enhancer. In clinical trials, orforglipron has been shown to reduce body weight and improve blood sugar control Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial+1.

The compound emerged from a drug-discovery program that identified a non-peptide molecule capable of binding the GLP-1 receptor. Structural studies in 2020 confirmed its unique binding mode, and early human trials established its pharmacokinetic profile: a long half-life supporting once-daily dosing, and food having only a modest effect on exposure Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants+1. Phase 3 programs (ACHIEVE in diabetes, ATTAIN in obesity) have since demonstrated efficacy across multiple populations Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial+2.

What the research shows

• In type 2 diabetes, adding orforglipron to metformin lowered HbA1c by up to 1.9% at 52 weeks, outperforming oral semaglutide at the doses tested Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
• In obesity with diabetes, 36 mg daily led to an average 9.6% body weight reduction over 72 weeks Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
• In people without diabetes, indirect comparisons suggest weight loss may be larger, though it may still be less than with high-dose oral semaglutide Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.
• Orforglipron also improved blood pressure, cholesterol, and other cardiometabolic risk markers Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes+1.

Current status

Orforglipron received FDA approval in 2026 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. It is marketed as Foundayo in tablet strengths of 5.5 mg, 9 mg, and 17.2 mg, which correspond to the 6 mg, 12 mg, and 36 mg capsule doses studied in trials Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.

Orforglipron works by mimicking the natural hormone GLP-1. It binds to the same receptor on cells in the pancreas, brain, and gut, producing effects that help control appetite and blood sugar.

The drug is a small molecule, not a protein, so it can be taken as a pill and absorbed directly into the bloodstream. Once it reaches the GLP-1 receptor, it turns on a signaling pathway inside the cell that raises a molecule called cyclic AMP The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. This leads to:

• Appetite reduction: Slower stomach emptying and signals to the brain that reduce hunger and food intake Orforglipron ( <scp>LY3502970</scp> ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants+1.
• Better insulin release: The pancreas releases more insulin only when blood sugar is high, helping to lower glucose safely Orforglipron ( <scp>LY3502970</scp> ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes.
• Less glucagon: The liver produces less excess sugar Orforglipron ( <scp>LY3502970</scp> ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes.

Unlike many other GLP-1 drugs, orforglipron shows what researchers call “biased signaling.” It strongly activates the G-protein pathway but barely recruits a protein called beta-arrestin. This may mean the receptor stays active on the cell surface longer rather than being pulled inside and desensitized The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron+1. Preclinical work suggests that even a low level of receptor engagement can produce a full biological response.

The drug has a long half-life (about 25–68 hours), so a single daily pill keeps levels stable Orforglipron ( <scp>LY3502970</scp> ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants+1. Food lowers absorption by around 20%, but not enough to matter clinically, so it can be taken without strict meal timing Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.

The effects of orforglipron have been measured across several large randomized trials. The main findings center on weight loss, blood sugar control, and cardiometabolic risk factors.

Weight loss

In a 72-week trial in people with obesity and type 2 diabetes, orforglipron 36 mg led to an average placebo-adjusted weight loss of about 7.1 percentage points more than placebo Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lower doses produced smaller losses. In people without diabetes, indirect analyses suggest placebo-adjusted loss may be around 9–11% at the highest dose Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. Weight loss tends to plateau around 48 weeks, and staying on the drug helps maintain the reduction Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial+1.

Glycemic control

In type 2 diabetes, orforglipron lowers HbA1c in a dose-dependent manner. In the ACHIEVE-3 trial, 12 mg and 36 mg reduced HbA1c by 1.71% and 1.91%, respectively, compared to 1.23% with oral semaglutide 7 mg and 1.47% with 14 mg after 52 weeks. Both doses were statistically superior to the semaglutide doses tested Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. When added to insulin glargine, 3–36 mg lowered HbA1c by 1.58–1.88% without an increase in severe hypoglycemia Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes.

Cardiometabolic improvements

Beyond weight and glucose, orforglipron has been shown to reduce systolic blood pressure by around 5 mmHg, raise HDL cholesterol, lower triglycerides, and reduce markers of inflammation like hsCRP Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes+1. These effects appear across doses above 12 mg and are consistent with the broader GLP-1 receptor agonist class.

Effect size vs. tolerability

The strongest effects come with the highest dose (36 mg), but that dose also causes the most gastrointestinal side effects and the highest dropout rate. Many people stay at 12 mg or 24 mg to balance benefit and comfort Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial+1.

Research protocols for orforglipron all involve oral, once-daily administration. Unlike injectable GLP-1 agonists, there is no injection training required, and the drug can be taken with or without food Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist+1.

Typical dosing regimens

Clinical trials used fixed maintenance doses of 3 mg, 6 mg, 12 mg, 24 mg, or 36 mg, always reached after a step-up titration period of several weeks Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial+1. A common community protocol mirrors this:

• Start at 3 mg daily for 2–4 weeks.
• If well tolerated, increase to 6 mg daily for another 2–4 weeks.
• Move to 12 mg daily. Many find this dose sufficient for appetite control and weight loss.
• For additional effect, some escalate to 24 mg and then 36 mg, holding at each step until gastrointestinal side effects subside Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.

In trials, the highest dose (36 mg) produced the greatest weight loss but also had the highest rate of treatment discontinuation due to nausea, vomiting, and diarrhea Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial+1.

Dosing by body weight

Trials did not use weight-based dosing, but heavier individuals often require higher fixed doses to achieve similar percentage weight loss. For example, a person weighing 90 kg may need 24–36 mg to get the same appetite suppression that a 70 kg person gets from 12 mg Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.

Duration of use

Studies have lasted 40–72 weeks, and weight maintenance benefits require ongoing treatment. Stopping typically leads to gradual regain of weight and loss of glycemic benefits Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial+1.

Route comparison

Orforglipron is an oral small molecule. It has high bioavailability (about 79%) and does not require reconstitution, refrigeration, or fasting Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants. This makes it more convenient than injectable GLP-1 drugs for many people, though the gastrointestinal side-effect burden remains comparable.

Orforglipron’s interactions with other substances mostly revolve around its effects on stomach emptying and glucose metabolism, rather than direct drug-drug metabolism conflicts. However, because it is broken down by CYP3A4 enzymes, strong inhibitors or inducers of that enzyme system require caution Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.

Key medication interactions

• Insulin and sulfonylureas: Adding orforglipron to these glucose-lowering drugs can increase the risk of hypoglycemia. In trials with basal insulin, no excess severe hypoglycemia was seen, but close monitoring is advised Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes.
• Other GLP-1 agonists: Combining orforglipron with semaglutide, liraglutide, or tirzepatide is not recommended outside of expert supervision because the effects on nausea, vomiting, and heart rate would likely be additive Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial+1.
• Oral semaglutide: While they share a target, they are different molecules. Switching from injectable semaglutide to orforglipron for weight maintenance has been studied and may be a feasible strategy Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
• SGLT2 inhibitors (e.g., dapagliflozin): The combination is mechanistically complementary but can raise dehydration risk due to combined fluid loss and reduced intake Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
• Drugs with narrow absorption windows: Because orforglipron slows stomach emptying, the peak absorption of some oral medications (like levothyroxine or certain pain relievers) may be delayed or reduced Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes.
• CYP3A4 interactions: The approved label suggests caution with strong CYP3A4 inhibitors, avoidance of strong inducers, and limiting simvastatin to 20 mg daily Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.

Supplement considerations

• Berberine, chromium, and other glucose-lowering supplements: These may add to the glucose-lowering effect, increasing the chance of low blood sugar if combined with diabetes medications Orforglipron ( <scp>LY3502970</scp> ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants.
• High-dose fish oil or magnesium citrate: These can worsen the diarrhea that is already common during dose escalation.
• Stimulants (caffeine, yohimbine): May compound the heart rate increase seen with orforglipron Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.

Conditions requiring extra care

People with a history of pancreatitis, severe gastroparesis, or rapid atrial fibrillation should use orforglipron only after a thorough risk assessment Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial+1.

Orforglipron is sometimes used with other compounds, but the evidence base for such combinations is still limited. The main principles come from the drug’s mechanism and the known effects of GLP-1 receptor activation.

With other incretin therapies

Stacking orforglipron with another GLP-1 agonist (e.g., semaglutide, tirzepatide) is generally avoided because the side effects on the gut and heart rate are likely to be additive, and there is no clear evidence of extra benefit Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial+1. Instead, switching sequentially has been studied: for example, moving from a once-weekly injectable GLP-1 drug to daily oral orforglipron to maintain weight loss Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.

With growth hormone secretagogues

Compounds like CJC-1295, ipamorelin, or MK-677 increase growth hormone, which can raise blood sugar. Orforglipron counteracts that by improving insulin sensitivity and lowering glucose. The net effect on body composition may depend on diet and exercise, but glucose should be monitored more closely than when using either agent alone Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.

With healing peptides

BPC-157, TB-500, and other tissue-repair peptides do not have known interactions with GLP-1 signaling. They are often used alongside orforglipron during weight-loss phases to support injury recovery, though no formal combination trials exist.

With stimulant fat burners

Adding high-dose caffeine, yohimbine, or synephrine to orforglipron can amplify nausea, reflux, and heart rate increases. Community practice suggests these are usually avoided during the early titration period.

In all cases, adding multiple agents increases the complexity of managing side effects, so single-therapy adjustment is preferred before exploring combinations.

Orforglipron is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management. It received marketing authorization in 2026 under the brand name Foundayo, and it is available as tablets in 5.5 mg, 9 mg, and 17.2 mg strengths Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison+1. The approved indication covers adults with obesity or overweight who also have at least one weight-related health condition.

In the European Union, orforglipron was among the medicines authorized in April 2026, also for obesity treatment Medicamentos novedosos autorizados en abril de 2026 en la UE y EE. UU. Information on approval in other countries is not available in this research corpus.

Prescription status

Orforglipron requires a prescription in the U.S. It is not a controlled substance and does not appear on any DEA schedule. As a branded, FDA-approved medicine, routine pharmacy compounding is generally restricted once commercial supply is available.

Sports and anti-doping

No anti-doping organization, including WADA, has listed orforglipron as a banned substance in the documents reviewed. GLP-1 receptor agonists are not considered performance-enhancing. However, athletes should verify current regulations with their sport's governing body before use.

The safety profile of orforglipron is dominated by dose-related gastrointestinal effects. These side effects are well characterized in randomized trials and are the main reason people stop treatment.

Common side effects

Most people experience some degree of nausea, diarrhea, vomiting, constipation, or decreased appetite, especially when starting the drug or increasing the dose Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial+1. In trials, 58–59% of those on 12–36 mg reported gastrointestinal issues, compared to 37–45% on oral semaglutide Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. About 6–10% stopped orforglipron due to side effects, mostly in the first weeks Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.

• Nausea is usually mild to moderate and improves over time.
• Vomiting and diarrhea can lead to dehydration if severe.
• Constipation and reflux are also reported.

Heart rate

Orforglipron consistently raises resting heart rate by 4–6 beats per minute on average. In the ACHIEVE-3 trial, the increase was about 3.7 bpm with 12 mg and 4.7 bpm with 36 mg, compared to 1–1.5 bpm with oral semaglutide Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. This is usually asymptomatic but could be a concern in people with heart rhythm disorders.

Pancreas and gallbladder

Lipase and amylase levels sometimes rise, but clinical pancreatitis has not been shown to occur more often than with placebo in existing analyses The Gastrointestinal Safety of Orforglipron, a <scp>GLP</scp> ‐1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta‐Analysis of Randomized Controlled Trials. Gallbladder events are a theoretical class concern, but orforglipron-specific data are limited.

Other considerations

• Rapid improvement in blood sugar can temporarily worsen diabetic retinopathy, so eye exams are recommended The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.
• The drug slows stomach emptying, which can increase risk during procedures requiring sedation The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.
• Allergic reactions are rare, and no thyroid cancer signal has been confirmed The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.

Monitoring

Regular check-ins during the first few months can catch persistent vomiting, rapid weight loss, or signs of dehydration. Many people find that slowing the dose increase and eating smaller, lower-fat meals helps tolerability.

Orforglipron has not been studied in pregnancy, breastfeeding, or in children, so it is not recommended in those groups.